Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03631407
Title Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | CAN

Facility Status City State Zip Country Details
Honor Health ( Site 0103) Scottsdale Arizona 85258 United States Details
California Cancer Associates for Research & Excellence ( Site 0100) Encinitas California 92024 United States Details
California Cancer Associates for Research & Excellence ( Site 0102) Fresno California 93720 United States Details
Florida Cancer Specialists (South Region) - Research Office ( Site 7001) Fort Myers Florida 33901-8101 United States Details
Tennessee Oncology, PLLC/The Sarah Cannon Research Institute ( Site 7000) Nashville Tennessee 37203 United States Details
Baylor Scott & White Medical Center - Temple ( Site 0104) Temple Texas 76508 United States Details
Cross Cancer Institute ( Site 0201) Edmonton Alberta T6G 1Z2 Canada Details
CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0204) Montreal Quebec H1T 2M4 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field